关于回购公司股份的进展公告：普洛药业股份有限公司于2025年2月19日召开第九届董事会第十次会议 审议通过了《关于回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司部 分股份，用于实施公司股权激励和员工持股计划。本次回购股份价格不超过人民币22元/股，回购资金 总额不低于人民币7500万元且不超过人民币15000万元。回购期限为自公司董事会审议通过回购股份方 案之日起12个月内。截至2025年3月31日，公司暂未通过回购专用证券账户以集中竞价交易方式回购公 司股份。公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托时间均符合相关规 定。公司未在可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发生之日或者在决策过程 中至依法披露之日内回购公司股份。公司以集中竞价交易方式回购股份符合委托价格不得为公司股票当 日交易涨幅限制的价格等要求。公司后续将根据公司股份回购方案并结合市场情况及公司资金安排，在 回购期限内继续实施本次回购股份方案，并将严格按照相关法律法规和规范性文件的规定及时履行信息 披露义务。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备31010 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-22 普洛药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励和员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告编号：2025-05） 及《关于回 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-21 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 3 月 28 日，普洛药业股份有限公司（以下简称"公司"）与招 商银行股份有限公司金华义乌支行（"招商银行"）签订《不可撤销担保书》（合 同编号：571HT250328T00018501）,同意为公司全资子公司浙江普洛家园药业有 限公司（以下简称"家园药业"）与招商银行签署的《借款合同》（合同编号： 571HT250328T000185）提供流动资金借款 2,000 万元连带责任保证，担保期限为 12 个月。 2、2025 年 3 月 28 日，公司与中国银行股份有限公司东阳支行（以下简称 "中国银行"）签订《保证合同》（合同编号：横店 2025 人保字 062 号），同 意为公司全资子公司山东普洛汉兴医药有限公司（以下简称"山东汉兴"）与中 国银行签署的《流动资金借款合同》（合同编号：横店 2025 人借字 062 号）中 的流动资金贷款 2,000 万元 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [7][20]. Core Views - The company experienced short-term fluctuations in its performance for 2024, with a revenue of 12.022 billion yuan, a year-on-year growth of 4.8%, and a net profit of 1.031 billion yuan, down 2.3% year-on-year. The operating cash flow showed strong performance, reaching 1.21 billion yuan, an increase of 17.2% [3][5][4]. - The CDMO (Contract Development and Manufacturing Organization) business is expected to see significant growth, with a project count increasing by 77% year-on-year, indicating a robust pipeline for future revenue [6][7]. - The antibiotic API and formulation sales are under short-term pressure, but the raw material and formulation business is projected to have a "front low and back high" trend in 2025, with improved profitability expected as the product matrix expands [6][7]. Financial Performance Summary - In 2024, the company achieved a revenue of 12.022 billion yuan, with a breakdown showing raw material drug revenue at 8.65 billion yuan (+8.3%), formulation revenue at 1.26 billion yuan (+0.5%), and CDMO revenue at 1.88 billion yuan (-6.1%). The overall gross margin for formulations improved to 60.8% (+7.7 percentage points) [5][6]. - The net profit forecast for 2025-2027 is adjusted to 1.15 billion yuan, 1.33 billion yuan, and 1.56 billion yuan, with growth rates of 12%, 15%, and 17% respectively [7][8]. - The company’s financial ratios indicate a stable outlook, with a projected P/E ratio decreasing from 17.4 in 2024 to 11.5 in 2027, reflecting anticipated growth in earnings [8][14].

Transaction Overview - The company is optimizing its asset structure through a transaction where its wholly-owned subsidiary, Zhejiang Puluo Debang Pharmaceutical Co., Ltd., transfers 100% equity and a debt of 6.9 million yuan in Sichuan Xinquan Dong Health Technology Co., Ltd. to Sichuan Jingxin Electric Co., Ltd. [1] - The transfer price is based on the net asset value of 26.4683 million yuan as of June 30, 2024, assessed by Shanghai Shenwei Asset Appraisal Co., Ltd. [1] Transaction Details - The transaction does not require approval from the board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2] - The buyer, Sichuan Jingxin Electric Co., Ltd., has total assets of 42.9828 million yuan and net assets of 9.5720 million yuan for the year 2024 [2] Target Company Information - The target company, Sichuan Xinquan Dong Health Technology Co., Ltd., has total assets of 5.6510 million yuan and a net asset deficit of 1.2635 million yuan for the year 2024 [3] - The target company reported no operating income for the first two months of 2025 and a net loss of 19.40 million yuan [3] Agreement Highlights - The transfer includes 100% equity and a debt of 6.9 million yuan [4] - The total transfer price for the equity is set at 30.18 million yuan, with a total of 35.08 million yuan to be deposited in a fund supervision account [4] Purpose and Impact of the Transaction - The transaction aims to further optimize the company's asset structure and aligns with its development strategy [5] - Post-transaction, the target company will no longer be included in the company's consolidated financial statements, and it is expected to increase the company's profit by approximately 27.60 million yuan for the year 2025 [5]

关于下属公司股权转让的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次交易概述 为进一步优化普洛药业股份有限公司（以下简称"公司"）的资产结构，基 于公司发展需要，公司全资子公司浙江普洛得邦制药有限公司（以下简称"得邦 制药"或"甲方"）与四川精信电器有限公司（以下简称"精信电器"或"乙方"） 签署了《股权转让暨债权转让协议》，得邦制药将持有的四川欣全动健康科技有 限公司（由横店集团成都分子实验室有限公司于 2025 年 1 月更名，以下简称"标 的公司"）100%股权以及享有的 690 万元债权转让给精信电器。本次转让价格以 标的公司截至 2024 年 6 月 30 日（评估基准日）经上海申威资产评估有限公司评 估的净资产值 2,646.83 万元（账面净资产值-580.58 万元）为依据，确定本次 100%股权转让价款为 3,018 万元，以及债权 690 万元，共计 3,708 万元人民币。 本次股权转让完成后，精信电器将直接持有标的公司 100%股权，得邦制药不再 持有标的公司股权。 根据深圳证券交易所《股票上市规则》和《上市公司自律监管 ...

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 编号：2025-02 | 投资者关系活动 | ■业绩说明会 | | --- | --- | | 类别 | | | 参与单位名称及 | 线上参与普洛药业2024年年度报告网上业绩说明会的投资者 | | 人员姓名 | | | 时间 | 2025年03月27日 15:00-16:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司接待人 员姓名 | 董事长 祝方猛先生 | | | 总经理 何春先生 | | | 独立董事 钱娟萍女士 | | | 副总经理兼董事会秘书 周玉旺先生 | | | 财务总监 张进辉先生 | | | 董事会办公室主任兼证券事务代表 关键先生 | | | 1.公司第三季度业绩不及预期，请说明原因及公司应对举 | | | 措？ 答:公司 2024 年第三季度业绩主要受到当期汇率波动影 响和制剂业务集采等政策影响。 | | 投资者关系活动 | 2.如何解决利润增长放缓与业务协同不足？2024 年公司 | | 主要内容介绍 | 营收同比增长 4.77%，但 ...

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [4][8]. Core Insights - The company reported a revenue of 12.022 billion yuan in 2024, representing a year-on-year growth of 4.77%, while the net profit attributable to shareholders decreased by 2.29% to 1.031 billion yuan [1][3]. - The CDMO (Contract Development and Manufacturing Organization) segment continues to show robust growth, with a significant increase in project numbers, indicating a strong future growth potential [2][4]. - The report highlights that the company's short-term performance is under pressure due to changes in the business environment, particularly in the raw material and formulation sectors, but the long-term competitive strength remains intact [1][4]. Financial Performance Summary - In 2024, the company achieved a total revenue of 12.022 billion yuan, with a year-on-year growth of 4.77% [1]. - The net profit attributable to shareholders for 2024 was 1.031 billion yuan, down 2.29% from the previous year [1]. - The CDMO segment generated revenue of 1.884 billion yuan, a decrease of 6.05% year-on-year, but the number of ongoing projects increased significantly [2]. - The raw material segment reported revenue of 8.651 billion yuan, with an 8.32% year-on-year growth, while the formulation segment achieved revenue of 1.256 billion yuan, growing by 0.51% [4][8]. Project and Market Dynamics - The company has a total of 1,601 quoted projects, a 77% increase year-on-year, with 996 ongoing projects, up 35% [2]. - The number of commercialized projects reached 355, reflecting a 25% increase, while the R&D phase projects grew by 42% to 641 [2]. - The API (Active Pharmaceutical Ingredient) projects also saw a 40% increase, with 22 projects already in production [2]. Valuation Metrics - The report projects net profits for 2025, 2026, and 2027 to be 1.129 billion yuan, 1.290 billion yuan, and 1.530 billion yuan, respectively, with year-on-year growth rates of 10%, 14%, and 19% [3][8]. - The current PE ratio is 16.9, with projections of 15.8, 13.8, and 11.6 for the following years [10].

证券研究报告 | 公司点评 | 化学制药 ❑ 财务表现：利润短期承压，经营质量高 2024 年公司实现营业收入 120.22 亿元，同比增长 4.77%；归母净利润为 10.31 亿 元，同比下滑 2.29%，扣非归母净利润为 9.84 亿元，同比下滑 4.09%。单季度 看，2024Q4 公司实现营业收入 27.32 亿元，同比下滑 8.15%；归母净利润为 1.61 亿元，同比下降 20.85%，扣非归母净利润为 1.53 亿元，同比下降 22.81%。2024 年经营活动产生的现金流净额 12.09 亿（远好于净利润），同比+17.20%，显示较 强的经营质量。 ❑ 成长能力： 原料药中间体稳健增长，CDMO&制剂未来动能足 原料药及中间体业务：量加速价趋稳。2024 年公司原料药中间体业务实现销售 收入 86.51 亿元（YOY8.32%），303、304 高端原料药生产车间已建成投用，标 志着企业高端制造能力再上新台阶。其中原料药中间体项目销量同比+9.37%，相 比 2023 年（YOY+4.28%）加速，显示出 2024 年行业需求持续高位以及公司较 强的竞争力。根据公司披露投资者关系活动交流纪 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to enter a trend of improving profitability due to the increasing revenue share from high-margin businesses such as CDMO and formulations, along with rising capacity utilization and production efficiency [1][10] - The financial performance shows short-term profit pressure but maintains high operational quality, with 2024 revenue at 12.022 billion yuan, a year-on-year increase of 4.77%, and a net profit of 1.031 billion yuan, down 2.29% year-on-year [1][2] Financial Performance Summary - In 2024, the company achieved revenue of 12.022 billion yuan, with a net profit of 1.031 billion yuan, reflecting a decline in profitability [1] - The cash flow from operating activities was 1.209 billion yuan, up 17.20% year-on-year, indicating strong operational quality [1] - The overall gross margin for 2024 was 23.85%, a decrease of 1.81 percentage points year-on-year, primarily due to a decline in the gross margin of the raw material and intermediate business [4] Growth Potential Summary - The raw material and intermediate business saw stable growth, with sales revenue of 8.651 billion yuan in 2024, an increase of 8.32% year-on-year [2] - The CDMO business maintained strong growth, with 1,601 quoted projects, a 77% increase year-on-year, and 996 ongoing projects, a 35% increase year-on-year [3] - The pharmaceutical business generated revenue of 1.256 billion yuan in 2024, with a focus on a multi-variety development strategy and a pipeline of 64 projects [4] Profitability Outlook - The company is expected to enter a period of improving profitability as the revenue share from high-margin businesses increases [10] - The projected earnings per share (EPS) for 2025-2027 are 1.00, 1.13, and 1.36 yuan, respectively, indicating a positive growth trajectory [11]